The Great GLP-1 Reset Has Begun

President Trump’s new Medicare deal with Eli Lilly & Company and Novo Nordisk has reshaped the economics of weight loss.

High-demand GLP-1 drugs such as Wegovy and Zepbound, once a $1,000-a-month treatment for a select few, will soon be available for about $245 under Medicare with a $50 copay.

This is more than a price change. It represents a fundamental shift in how obesity and metabolic health may be treated across the country.

The broader impact is not only about cost reduction. It is about what comes next—how millions of new users will enter the GLP-1 era, how telehealth companies may need to adapt, and how sustainable health outcomes will depend on behavior as much as access.

From Limited Access to Coverage

Until recently, GLP-1 medications were primarily accessible through boutique telehealth platforms and compounding pharmacies. Companies such as Ro, Hims & Hers, and Mochi Health built billion-dollar valuations by providing convenience, privacy, and personalized programs.

Trump’s “Most Favored Nation” pricing agreement changes that landscape.

By securing lower list prices in exchange for expanded federal coverage, Eli Lilly and Novo Nordisk have shifted the focus to scale. Analysts estimate the move could open access to more than 30 million new patients, creating a $27-billion annual opportunity while challenging the subscription-based models in telehealth.

Telehealth companies now face a pivotal moment. The question is how they will demonstrate value once prescription access becomes widely available.

The Changing Economics of Telehealth

The telehealth industry grew rapidly by offering subscription programs that included GLP-1 prescriptions, coaching, and compounding services at $350 to $500 per month. That model relied on exclusivity and convenience.

With branded GLP-1s now covered by Medicare, those margins will shrink. Providers and platforms will need to focus on clinical outcomes, patient engagement, and long-term adherence.

The companies that succeed in this next phase will be the ones that support patients in maintaining consistency over time. Sustained progress, not rapid prescribing, will define success.

This shift highlights the growing importance of behavioral tools like Shapa.

Beyond the Scale: Shapa’s Numberless Approach

The GLP-1 era is changing how people think about metabolism, appetite, and long-term weight management. Yet even the most effective medications cannot replace habit formation.

That is why Shapa was created—to measure progress in a way that reflects real behavioral change.

The Shapa Numberless Scale® does not display a daily number. Instead, it evaluates trends in weight stability and consistency, guiding people toward sustainable health without the stress of daily fluctuations.

Rapid weight changes, which can occur on GLP-1 treatments, can make motivation tied to the scale rather than to healthy routines. Shapa reframes progress around behavior, tracking nutrition, movement, sleep, and mindset.

Shapa was co-founded by Dan Ariely, Professor of Psychology and Behavioral Economics at Duke University. Ariely’s research into human motivation and decision-making informs the system’s design:

“Numbers can motivate, but they can also manipulate. When we remove the number, we make space for behavior.”

As GLP-1 medications become more accessible, tools that promote behavioral awareness will be essential for maintaining results beyond the prescription.

Longevity, Personalization, and the Next Health Frontier

GLP-1 medications have also found a role in wellness and longevity circles. Microdosing, compounding, and precision dosing are being used not only for weight management but also for metabolic optimization and performance.

Personalization, however, cannot rely on medication alone. It requires behavioral data that reflects daily patterns.

Shapa’s system tracks these behaviors and provides adaptive feedback, turning health progress into an ongoing cycle of insight and improvement.

From Policy Shift to Public Health Progress

The deal’s framing as “bringing obesity care to every American senior” signals a new approach to obesity as a medical condition. Medicare now formally recognizes obesity as a factor in chronic disease, rather than as a cosmetic concern.

It is a meaningful step toward expanding access to care. Yet access alone does not guarantee lasting results.

When medications are discontinued, behavioral habits built alongside treatment will determine long-term outcomes.

The GLP-1 reset changes who can afford treatment. The next evolution will determine who can sustain wellness after treatment ends.

The Future of Weight Management Is Behavior First

The GLP-1 revolution began as a pharmaceutical story. It is now becoming a behavioral one.

These drugs can influence appetite and metabolism, but they cannot replace consistency, discipline, or emotional resilience.

Sustainable change begins with understanding daily habits and staying engaged with one’s health journey.

Shapa empowers this process by shifting focus from numbers to patterns, helping people see health as a continuum rather than a single measurement.

Meaningful progress does not start with a pill or a price. It starts with awareness, intention, and measurable behavior change.

And that is what Shapa helps people achieve.